Lundbeck funds propel Ossianix towards Series A in 2013
This article was originally published in Scrip
A strategic investment from CNS specialist H. Lundbeck A/S will allow Ossianix to undertake preclinical proof-of-concept studies that, in turn, could permit the Philadelphia-based start-up to raise further money in a Series A round sometime in 2013, according to CEO Frank Walsh.
You may also be interested in...
By using the binding region of shark antibodies as a carrier to cross the blood-brain barrier, Ossianix reckons it has made significant progress against an issue that has held back the development of CNS-active neurological therapies.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.